Novartis gets bragging rights on first U.S. biosim. But will its Neupogen copy sell?

March 6, 2015 2:56 PM

12 0

It's been a long, long regulatory road, but the first FDA-approved biosimilar--a copy of Amgen's ($AMGN) Neupogen from Novartis' ($NVS) generics unit, Sandoz--is finally here. But that doesn't mean it'll catch on right away, as the Swiss pharma's CEO has been first to admit.

Friday, U.S. regulators green-lighted Zarxio for all 5 indications on white-blood-cell-booster Neupogen's label, a move Sandoz's global head of biopharmaceuticals, Carol Lynch, called a "significant milestone for the United States healthcare system."

Read more

To category page